comparemela.com

Cart22 News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Cellectis Announces Poster Presentation on BALLI-01 at the European Hematology Association (EHA) 2023

BALLI-01 abstract demonstrates safety and preliminary efficacy of UCART22 in heavily pretreated r/r B-ALL populationNEW YORK, May 11, 2023 Cellectis , a clinical-stage biotechnology company. | May 11, 2023

North carolinaUnited statesNew yorkFrance generalMark frattiniAshleyr robinsonNicolas boisselPascalyne wilsonArthur strilCellectis the company euronext growthSecurities exchange commissionEuropean hematology associationEuronext growthHybrid congressChief medical officerUpdated results

Cellectis Provides Business Update and Reports Financial Results for First Quarter 2023

First r/r ALL patient dosed in Europe with Cellectis’ UCART22 product candidate manufactured in-houseCellectis implements CLLS52 for the first time in the clinic with Sanofi’s. | May 4, 2023

United statesNorth carolinaFrance generalNew yorkAshleyr robinsonPascalyne wilsonArthur strilInternational accounting standards boardBarclays capital incResearch data preclinical programsAmerican society of hematologyAmerican society of clinical oncologyCibus globalAmerican society of geneEuropean investment bankExchange commission

Cellectis Announces Dosing of the First Patient in Europe with its In-house Manufactured Product Candidate UCART22

UCART22 is currently the most advanced allogeneic CAR T-cell product in development for relapsed or refractory B-cell acute lymphoblastic leukemia The BALLI-01 study is actively enrolling patients. | April 11, 2023

France generalNorth carolinaUnited statesNew yorkArthur strilMark frattiniPascalyne wilsonAshleyr robinsonCellectis the company euronext growthSecurities exchange commissionEuronext growthDose limiting toxicityChief medical officerLive webcastNasdaq global marketPrivate securities litigation reform act

Cellectis Reports Encouraging Clinical Data from BALLI-01 Study in Relapsed/Refractory B-cell Acute Lymphoblastic Leukemia, and Preclinical Data from TALGlobin01 at the 63rd American Society of Hematology Annual Meeting

Cellectis’ Proprietary Product Candidate UCART22 was Administered after Lymphodepletion with Fludarabine, Cyclophosphamide and Alemtuzumab with no Dose-Limiting Toxicities in BALLI-01. | December 11, 2021

New yorkUnited statesFrance generalNorth carolinaAshleyr robinsonMargaret gandolfoPascalyne wilsonCarrie brownsteinArthur strilMeeting of the american society hematologyCellecti proprietary product candidateDose limiting toxicitiesProlonged host lymphocyte suppressionCurrently enrollingDose level threeClinical data

vimarsana © 2020. All Rights Reserved.